Clinical trials: Temozolomide, completed
Glioma, Glioblastoma Multiforme
Temozolomide Chronotherapy for High Grade Glioma
Temozolomide (TMZ) is the chemotherapy drug approved by the FDA to increase survival in glioblastoma (GBM) patients beyond surgical resection and radiation therapy alone.
- Trial name
- NCT02781792
- Testing
- Temozolomide, Functional Assessment of Cancer Therapy - Brain, ActTrust Condor Instrument Watch
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Washington University School of Medicine
Glioblastoma, Gliosarcoma
Sorafenib in Newly Diagnosed High Grade Glioma
This is a phase I study to evaluate the safety and tolerability of Sorafenib in combination with Temodar and radiation therapy in patients with newly diagnosed high grade glioma (glioblastoma, gliosarcoma, anaplastic astrocytoma…
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
- Trial name
- NCT00884416
- Testing
- Sorafenib dose escalation
- Where
- Switzerland
- Volunteers
- 17 people
- Sponsor
- University Hospital, Geneva
Colorectal Adenocarcinoma
Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer
This study will test whether the combination of cisplatin, nivolumab, and temozolomide is an effective treatment for in people with advanced and/or metastatic colorectal cancer that is mismatch repair-proficient (MMR-proficient).
- Trial name
- NCT04457284
- Testing
- Temozolomide (TMZ), Cisplatin, Nivolumab
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
High Grade Glioma
Expedited Laser Interstitial Thermal Therapy + Chemoradiation For Newly Diagnosed High Grade Gliomas
The investigators of this study want to see if shortening the total treatment time for brain tumors is safe.The treatment for participant's brain tumors is laser surgery (Laser Interstitial Thermal Therapy (LITT)) followed by…
- Trial name
- NCT02970448
- Testing
- LITT, Radiation therapy, Temozolomide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Case Comprehensive Cancer Center
Neuroblastoma, Medulloblastoma
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
The purpose of this research study is to evaluate a new investigational drug (TPI 287) for neuroblastoma and medulloblastoma both alone and in combination with temozolomide (a currently approved drug).
- Conditions
- Neuroblastoma, Medulloblastoma, Relapse
- Trial name
- NCT00867568
- Testing
- TPI 287
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Giselle Sholler
Gliosarcoma, MGMT-Unmethylated Glioblastoma
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
This phase II/III trial compares the usual treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab in treating patients with newly diagnosed MGMT…
- Trial name
- NCT04396860
- Testing
- Contrast-enhanced Magnetic Resonance Imaging, Ipilimumab, Nivolumab
- Where
- 285 sites in United States
- Volunteers
- 159 people
- Sponsor
- National Cancer Institute (NCI)
Glioma
Hypofractionated IMRT With Temozolomide for HGG
To evaluate safety and feasibility of hypofractionated IMRT in addition to chemotherapy, concomitant and adjuvant, in patients with newly diagnosed HGGs after surgery.
- Trial name
- NCT02082119
- Testing
- Hypofractionated IMRT
- Where
- Italy
- Volunteers
- 82 people
- Sponsor
- Istituto Clinico Humanitas
Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity
Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors
RATIONALE: Learning whether temozolomide changes semen or sperm in patients with brain tumors may help doctors learn about the long-term effects of treatment and plan the best treatment.
- Conditions
- Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity, Infertility
- Trial name
- NCT00499798
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Glioblastoma Multiforme
Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
This study will combine the chemotherapy agent temozolomide with the investigational drug SCH66336 (an agent which interferes with new cell growth).
- Trial name
- NCT00038493
- Testing
- Temozolomide and SCH66336
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Primary Glioblastoma
Carbon Ion Radiotherapy for Primary Glioblastoma
Treatment standard for patients with primary glioblastoma (GBM) is combined radiochemotherapy with temozolomide (TMZ). Radiation is delivered up to a total dose of 60 Gy using photons.
- Trial name
- CLEOPATRA (NCT01165671)
- Testing
- Carbon Ion Radiotherapy, Proton Radiotherapy
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- University Hospital Heidelberg
Neuroblastoma
Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children
The purpose of this study is to investigate whether Bevacizumab (an anti-VEGF monoclonal antibody) added to a backbone chemotherapy regimen (Temozolomide, Irinotecan-Temozolomide or Topotecan-Temozolomide) demonstrates activity…
- Trial name
- BEACON (NCT02308527)
- Testing
- Bevacizumab, Temozolomide, Irinotecan
- Where
- 10 sites in Austria, Belgium and 8 more
- Volunteers
- 225 people
- Sponsor
- University of Birmingham
Metastatic, Cerebral Primitive Neuroectodermal Tumors
Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years
Primary objective : To increase the 3 year progression-free survival from 40% to 60%. Patients included : metastatic, cerebral primitive neuroectodermal tumors in children aged over 5 years.
- Trial name
- NCT00936156
- Testing
- Chemotherapy (carboplatin, etoposide, thiotepa)
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Malignant Neoplasms of Brain
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Vaccines may help the body build an effective immune response to kill cancer cells. Radiation therapy uses high-energy x-rays to kill cancer cells.
- Trial name
- ATTAC (NCT00639639)
- Testing
- tetanus toxoid, therapeutic autologous dendritic cells, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Gary Archer Ph.D.
Newly Diagnosed Glioblastoma Multiforme
Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme
The purpose of this study is to test the safety and effects of a combination of a study drug, Lapatinib, plus the administration of standard radiation therapy and an FDA approved drug Temozolomide (chemotherapy agent) in patients…
- Trial name
- NCT01591577
- Testing
- Lapatinib/Temozolomide/radiation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Glioblastoma
Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma
A phase 2 clinical trial for the efficacy and safety of low dose Temozolomide plus metformin as combination chemotherapy compared with low dose Temozolomide plus placebo in patient with recurrent or refractory Glioblastoma
- Trial name
- METT (NCT03243851)
- Testing
- Temozolomide+Metformin
- Where
- 12 sites in South Korea
- Volunteers
- 81 people
- Sponsor
- Yong-Kil Hong
Brain and Central Nervous System Tumors
Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma
RATIONALE: Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT01390571
- Testing
- olaparib, temozolomide, gene expression analysis
- Where
- 7 sites in United Kingdom
- Volunteers
- 34 people
- Sponsor
- Cancer Research UK
Adult Glioblastoma, Adult Gliosarcoma
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
This randomized phase II trial is studying the side effects and how well giving bevacizumab together with irinotecan or temozolomide works in treating patients with recurrent or refractory glioblastoma multiforme or gliosarcoma.
- Conditions
- Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Trial name
- NCT00433381
- Testing
- Bevacizumab, Irinotecan Hydrochloride, Temozolomide
- Where
- 93 sites in United States
- Volunteers
- 123 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias
RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00098436
- Testing
- laromustine, temozolomide
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Vion Pharmaceuticals
Pediatric Cancer
TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide
Non-randomized, international, multi-centre, open-label, single arm study to determine the pharmacokinetic (PK) parameters of a single dose of an oral suspension of temozolomide (KIMOZO) in the pediatric population aged 1 year…
- Trial name
- NCT04610736
- Testing
- Temozolomide Oral Suspension
- Where
- 11 sites in France, Germany and 3 more
- Volunteers
- 49 people
- Sponsor
- Orphelia Pharma
Primary Brain Tumor, Glioblastoma
Temozolomide in Elderly Patients With KPS < 70
The management of glioblastoma in elderly patients with poor performance status (KPS<70) is unsettled. This single arm phase 2 trial trial was designed to evaluate the efficacy and safety of temozolomide alone in this population
- Trial name
- TAG (NCT01242566)
- Testing
- Temozolomide
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris